Bio-Rad Laboratories (BIO) Competitors $247.52 -3.29 (-1.31%) As of 07/15/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BIO vs. MTD, WAT, ILMN, TECH, CRL, BRKR, PACB, HBIO, TMO, and AShould you be buying Bio-Rad Laboratories stock or one of its competitors? The main competitors of Bio-Rad Laboratories include Mettler-Toledo International (MTD), Waters (WAT), Illumina (ILMN), Bio-Techne (TECH), Charles River Laboratories International (CRL), Bruker (BRKR), Pacific Biosciences of California (PACB), Harvard Bioscience (HBIO), Thermo Fisher Scientific (TMO), and Agilent Technologies (A). These companies are all part of the "life sciences tools & services" industry. Bio-Rad Laboratories vs. Its Competitors Mettler-Toledo International Waters Illumina Bio-Techne Charles River Laboratories International Bruker Pacific Biosciences of California Harvard Bioscience Thermo Fisher Scientific Agilent Technologies Bio-Rad Laboratories (NYSE:BIO) and Mettler-Toledo International (NYSE:MTD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk. Is BIO or MTD more profitable? Mettler-Toledo International has a net margin of 22.17% compared to Bio-Rad Laboratories' net margin of -85.16%. Bio-Rad Laboratories' return on equity of 4.32% beat Mettler-Toledo International's return on equity.Company Net Margins Return on Equity Return on Assets Bio-Rad Laboratories-85.16% 4.32% 3.03% Mettler-Toledo International 22.17%-556.22%26.27% Do institutionals and insiders hold more shares of BIO or MTD? 65.2% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 95.1% of Mettler-Toledo International shares are owned by institutional investors. 17.8% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 0.8% of Mettler-Toledo International shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, BIO or MTD? Bio-Rad Laboratories has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Mettler-Toledo International has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500. Which has stronger earnings and valuation, BIO or MTD? Mettler-Toledo International has higher revenue and earnings than Bio-Rad Laboratories. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBio-Rad Laboratories$2.57B2.62-$1.84B-$76.20-3.25Mettler-Toledo International$3.87B6.25$863.14M$40.1029.06 Does the media favor BIO or MTD? In the previous week, Bio-Rad Laboratories had 4 more articles in the media than Mettler-Toledo International. MarketBeat recorded 18 mentions for Bio-Rad Laboratories and 14 mentions for Mettler-Toledo International. Mettler-Toledo International's average media sentiment score of 1.09 beat Bio-Rad Laboratories' score of 0.39 indicating that Mettler-Toledo International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Rad Laboratories 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Mettler-Toledo International 11 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate BIO or MTD? Bio-Rad Laboratories presently has a consensus price target of $324.25, suggesting a potential upside of 31.00%. Mettler-Toledo International has a consensus price target of $1,280.90, suggesting a potential upside of 9.92%. Given Bio-Rad Laboratories' stronger consensus rating and higher possible upside, equities research analysts clearly believe Bio-Rad Laboratories is more favorable than Mettler-Toledo International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Rad Laboratories 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Mettler-Toledo International 0 Sell rating(s) 6 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.45 SummaryMettler-Toledo International beats Bio-Rad Laboratories on 11 of the 16 factors compared between the two stocks. Get Bio-Rad Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIO vs. The Competition Export to ExcelMetricBio-Rad LaboratoriesMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$6.83B$10.37B$5.61B$20.82BDividend YieldN/A2.09%4.23%3.65%P/E Ratio-3.2516.6928.5427.17Price / Sales2.6228.91430.1147.97Price / Cash24.1322.6736.0222.28Price / Book1.063.598.144.56Net Income-$1.84B$233.40M$3.24B$995.22M7 Day Performance-2.14%-3.21%0.17%-1.16%1 Month Performance6.54%1.23%5.95%3.18%1 Year Performance-21.29%-19.76%26.22%6.83% Bio-Rad Laboratories Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIOBio-Rad Laboratories4.6788 of 5 stars$247.52-1.3%$324.25+31.0%-18.1%$6.83B$2.57B-3.257,700News CoverageAnalyst DowngradeAnalyst RevisionMTDMettler-Toledo International3.9731 of 5 stars$1,188.28-1.7%$1,300.36+9.4%-14.2%$24.69B$3.87B29.6317,300Positive NewsWATWaters4.873 of 5 stars$346.35-1.1%$388.00+12.0%-4.3%$20.61B$2.96B31.437,600Trending NewsAnalyst ForecastILMNIllumina4.8399 of 5 stars$97.15-3.6%$127.39+31.1%-16.7%$15.38B$4.37B-16.009,030TECHBio-Techne4.8686 of 5 stars$51.53-3.0%$72.00+39.7%-33.4%$8.08B$1.16B62.843,100News CoverageCRLCharles River Laboratories International4.8137 of 5 stars$153.93-2.0%$171.85+11.6%-28.6%$7.56B$4.05B-236.8220,100Positive NewsBRKRBruker4.9775 of 5 stars$41.27-2.8%$52.89+28.2%-33.8%$6.25B$3.37B79.3711,396Positive NewsHigh Trading VolumePACBPacific Biosciences of California1.8313 of 5 stars$1.47-8.1%$2.06+40.2%-11.1%$441.13M$152.36M-0.53730Gap DownHBIOHarvard Bioscience4.2307 of 5 stars$0.44-2.2%$3.00+577.2%-88.0%$19.59M$94.14M-0.34490TMOThermo Fisher Scientific4.9917 of 5 stars$418.76-2.5%$604.05+44.2%-23.1%$158.08B$42.88B24.56125,000Positive NewsUpcoming EarningsDividend AnnouncementAAgilent Technologies4.8143 of 5 stars$119.21-1.8%$140.92+18.2%-13.6%$33.86B$6.51B29.4317,900 Related Companies and Tools Related Companies Mettler-Toledo International Alternatives Waters Alternatives Illumina Alternatives Bio-Techne Alternatives Charles River Laboratories International Alternatives Bruker Alternatives Pacific Biosciences of California Alternatives Harvard Bioscience Alternatives Thermo Fisher Scientific Alternatives Agilent Technologies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BIO) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Rad Laboratories, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bio-Rad Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BIO Stock Alerts